Plitidepsin Could Treat COVID-19, Preclinical Data Suggest Plitidepsin Could Treat COVID-19, Preclinical Data Suggest
Early evidence for plitidepsin, an antiviral that has been studied for the treatment of multiple myeloma, could be repurposed as a therapy against COVID-19.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - January 28, 2021 Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news

Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world a...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

In preclinical models, antiviral better inhibits COVID-19 than Remdesivir; further studies warranted
(American Association for the Advancement of Science) Working in preclinical models, researchers report that plitidepsin, a drug with limited clinical approval for the treatment of multiple myeloma, is more potent against SARS-CoV-2 than remdesivir, an antiviral that received FDA emergency use authorization for the treatment of COVID-19 in 2020. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 25, 2021 Category: International Medicine & Public Health Source Type: news

Renal Insufficiency May Worsen Multiple Myeloma Outcomes
Risk for disease progression or death increased for those with renal insufficiency in relapsed/refractory, newly diagnosed MM (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 22, 2021 Category: Cancer & Oncology Tags: Nephrology, Oncology, Journal, Source Type: news

Renal Insufficiency May Worsen Multiple Myeloma Outcomes
FRIDAY, Jan. 22, 2021 -- For patients with multiple myeloma (MM), those with renal insufficiency (RI) have an increased risk for disease progression or death, according to a systematic review and meta-analysis published online Jan. 8 in Leukemia... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 22, 2021 Category: Pharmaceuticals Source Type: news

Whole body imaging detects myeloma in more patients, treatment initiated earlier
(King's College London) Researchers from King's College London have shown that whole body magnetic resonance imaging (WBMRI) not only detects more myeloma-defining disease than positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) but that it also allows critical treatment to be initiated earlier. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 21, 2021 Category: Cancer & Oncology Source Type: news

Designer DNA therapeutic wipes out cancer stem cells, treats multiple myeloma in mice
(University of California - San Diego) UC San Diego study supports launch of Phase I clinical trial to test a designer DNA agent -- an antisense oligonucleotide that targets a gene called IRF4 -- in patients with multiple myeloma. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 20, 2021 Category: Biology Source Type: news

Expert Alert: What's on the horizon for multiple myeloma and other blood cancers
ROCHESTER, Minnesota -- World Cancer Day is Feb. 4, 2021, highlighting how everyone can help reduce the global burden of cancer. In 2018, there were 17.0 million new cancer cases and 9.5 million cancer deaths worldwide. The three major types of blood cancer are leukemia, lymphoma and myeloma. Multiple myeloma is a cancer that forms [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - January 20, 2021 Category: Databases & Libraries Source Type: news

DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to th...
Source: Johnson and Johnson - January 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Advances in Multiple Myeloma From ASH 2020 Advances in Multiple Myeloma From ASH 2020
Breakthroughs in multiple myeloma from ASH 2020 include transplant studies in newly diagnosed patients, triple therapy in early relapse, and CAR T-cell as well as bispecific therapy in later relapse.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Janssen Initiates Rolling Submission of a Biologics License Application to U.S. FDA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
December 21, 2020 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the initiation of a rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adults with relapsed and/or refractory multiple myeloma.“We are committed to innovation in cell therapy and advancing the science of multiple myeloma to improve patients’ lives,” said Pete...
Source: Johnson and Johnson - December 21, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA approves selinexor for refractory or relapsed multiple myeloma
On December 18, 2020, the Food and Drug Administration approved selinexor (XPOVIO, Karyopharm Therapeutics Inc.) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 18, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Karyopharm Announces FDA Approval of Xpovio (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
NEWTON, Mass., Dec. 18, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial stage pharmaceutical company pioneering novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 18, 2020 Category: Drugs & Pharmacology Source Type: news

$10 million gift supports new myeloma research center at Ohio State
(Ohio State University Wexner Medical Center) The OSUCCC - James has received a $10 million gift from the Paula and Rodger Riney Foundation to establish the Riney Family Foundation Myeloma Center for Advanced Research Excellence. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2020 Category: Cancer & Oncology Source Type: news

Durable Responses With Anti-BCMA CAR T-cell for Multiple Myeloma Durable Responses With Anti-BCMA CAR T-cell for Multiple Myeloma
For patients with heavily-pretreated multiple myeloma, responses seen with the novel chimeric antigen receptor T-cell construct ciltacabtagene autoleucel (cilta-cel) have also been durable.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 9, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Five-Minute SC Injection of Daratumumab in R/R Multiple Myeloma Five-Minute SC Injection of Daratumumab in R/R Multiple Myeloma
The subcutaneous formulation of daratumumab in combination with pomalidomide and dexamethasone showed significant improvement in progression-free survival.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 9, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

ASH: Adding Subcutaneous Daratumumab Slows Advanced Multiple Myeloma
Subcutaneous daratumumab plus pomalidomide and dexamethasone reduces risk of progression, death in relapsed/refractory MM (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 8, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news

ASH: Adding Subcutaneous Daratumumab Slows Advanced Multiple Myeloma
TUESDAY, Dec. 8, 2020 -- For patients with relapsed/refractory multiple myeloma (RRMM), subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) reduces the risk of progression or death compared with Pd alone, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 8, 2020 Category: Pharmaceuticals Source Type: news

Fixed Duration Ibrutinib/Venetoclax Feasible for Some CLL/SLL Fixed Duration Ibrutinib/Venetoclax Feasible for Some CLL/SLL
For patients with heavily pretreated multiple myeloma, responses seen with the novel chimeric antigen receptor T-cell (CAR T-cell) construct ciltacabtagene autoleucel have also been durable.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 8, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New treatment uncovered for AL amyloidosis to be announced at ASH Meeting
(SWOG) Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that isatuximab, a monoclonal antibody approved for the treatment of multiple myeloma, can effectively treat relapsed refractory AL amyloidosis, findings to be announced at the 2020 Annual Meeting of the American Society of Hematology (ASH), held virtually December 5-8, 2020. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2020 Category: Cancer & Oncology Source Type: news

Janssen Presents First Data from the Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma
December 5, 2020 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial data for the Phase 1 first-in-human dose escalation study of talquetamab (JNJ-64407564) for the treatment of relapsed or refractory multiple myeloma (NCT03399799). Talquetamab is a first-in-class, and the only investigational bispecific antibody that targets both GPRC5D, a novel multiple myeloma target, and CD3 on T-cells. Initial results for both the subcutaneous (SC) and intravenous (IV) formulations show encouraging clinical activity against the GPRC5D target, which is highly expressed on multip...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Updated Results from the Phase 1 Study of the BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma
This study evaluated the ability of teclistamab to induce cytotoxicity and T-cell activation.About TeclistamabTeclistamab is an investigational bispecific antibody targeting both BCMA and CD3. BCMA, B-cell maturation antigen, is expressed at high levels on multiple myeloma cells.[3],[4],[5],[6],[7] Teclistamab redirects CD3-positive T-cells to BCMA-expressing myeloma cells to induce cytotoxicity of the targeted cells.5,6 Results from preclinical studies demonstrate that teclistamab kills myeloma cell lines and bone marrow-derived myeloma cells from heavily pretreated patients.6 Teclistamab is currently being evaluated in a...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Early, Deep, Durable Responses of Ciltacabtagene Autoleucel (cilta-cel) Observed in Phase 1b/2 CARTITUDE-1 Study Show Potential of BCMA CAR-T in Treatment of Heavily Pretreated Patients with Multiple Myeloma
December 5, 2020 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the combined Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. These data, presented as an oral presentation at the American Society of Hematology (ASH) 2020 Annual Meeting (Abstract #177), continued to demonstrate a very hig...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

ASH: Off-the-shelf immune drug shows promise in aggressive multiple myeloma
(University of Pennsylvania School of Medicine) A subcutaneous injection of the immune-boosting drug teclistamab was found to be safe and elicit responses in a majority of patients with relapsed or refractory multiple myeloma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 5, 2020 Category: Cancer & Oncology Source Type: news

Difficult-to-treat multiple myeloma – NICE recommendation
Around 5,700 cases of multiple myeloma are diagnosed each year in the UK. NICE has recommended a new option for people with difficult-to-treat multiple myeloma. (Source: NHS Networks)
Source: NHS Networks - November 26, 2020 Category: UK Health Source Type: news

Circulating miRNA for Early Diagnosis of Multiple Myeloma Circulating miRNA for Early Diagnosis of Multiple Myeloma
Circulating microRNAs (miRNAs) could be a potential noninvasive biomarker for early diagnosis of multiple myeloma, according to the results of a meta-analysis.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 25, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Triplet Therapy Slows Refractory Multiple Myeloma
WEDNESDAY, Nov. 18, 2020 -- A once-weekly regimen of selinexor, bortezomib, and dexamethasone slows the progression of relapsed or refractory multiple myeloma, according to a study published in the Nov. 14 issue of The Lancet. Sebastian Grosicki,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 18, 2020 Category: Pharmaceuticals Source Type: news

Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2020 -- (Healthcare Sales & Marketing Network) -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering ... Biopharmaceuticals, Oncology, Personnel Sutro Biopharma, XpressCF+, multiple myeloma, non-Hodgkin lymphom (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 18, 2020 Category: Pharmaceuticals Source Type: news

Multiple Myeloma: Deadly to Chronic
Title: Multiple Myeloma: Deadly to ChronicCategory: Diseases and ConditionsCreated: 11/13/2020 12:00:00 AMLast Editorial Review: 11/13/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - November 13, 2020 Category: Cancer & Oncology Source Type: news

Homecare for Bortezomib Safe and Reduces Hospital Visits in Myeloma Patients Homecare for Bortezomib Safe and Reduces Hospital Visits in Myeloma Patients
Home administration of bortezomib by the patient or a relative is safe and reduces hospital visits for these immunosuppressed patients.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 11, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutane...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting
Basel, 5 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition from 5 – 8 December 2020. Eleven Roche medicines will be featured in more than 80 abstracts, including 22 oral presentations. With studies spanning 16 blood disorders, including non-Hodgkin lymphoma (NHL), leukaemia, multiple myeloma (MM) and haemophilia A, these data highlight the strength and breadth o f Roche’s haematology portfolio and pipeline, and commitment to de...
Source: Roche Media News - November 5, 2020 Category: Pharmaceuticals Source Type: news

Roche to present new data across 16 blood disorders at the American Society of Hematology 2020 Annual Meeting
Basel, 5 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition from 5 – 8 December 2020. Eleven Roche medicines will be featured in more than 80 abstracts, including 22 oral presentations. With studies spanning 16 blood disorders, including non-Hodgkin lymphoma (NHL), leukaemia, multiple myeloma (MM) and haemophilia A, these data highlight the strength and breadth o f Roche’s haematology portfolio and pipeline, and commitment to de...
Source: Roche Investor Update - November 5, 2020 Category: Pharmaceuticals Source Type: news

Myeloma-Induced Acute Kidney Injury: Medicine vs Machine Myeloma-Induced Acute Kidney Injury: Medicine vs Machine
Higher-tech or more aggressive treatment doesn't necessarily mean better, cautions Tejas Desai, MD, in his review of studies on treatment strategies for myeloma-induced acute kidney injury.Medscape Nephrology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 2, 2020 Category: Consumer Health News Tags: Nephrology Viewpoint Source Type: news

Small study supports radiation before CAR-T therapy
A small, retrospective study suggests that radiation therapy may be administered...Read more on AuntMinnie.comRelated Reading: PET with Axumin boosts prostate cancer outcomes Single-session SBRT speeds treatment of lung metastases New radiotracer increases multiple myeloma survival ASTRO: Radiation can nix side effects of T-cell therapy UPenn gets $12M grant for new cancer therapy center (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 28, 2020 Category: Radiology Source Type: news

Penn Study supports use of radiation before CAR therapy for multiple myeloma
(University of Pennsylvania School of Medicine) Administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was found to be safe and undisruptive to CAR T therapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 26, 2020 Category: Cancer & Oncology Source Type: news

Multiple Myeloma Treatment: What ’s New?
Is there anything new to treat multiple myeloma, a type of blood cancer? Cutting-edge drugs target and kill cancer cells and use the power of your immune system to fight cancer. (Source: WebMD Health)
Source: WebMD Health - October 20, 2020 Category: Consumer Health News Source Type: news

Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 ...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Anticancer compounds for B cell cancer therapy targeting cellular stress response
(The Wistar Institute) Wistar and collaborators from the University of Notre Dame are developing anticancer compounds targeting a pathway of the endoplasmic reticulum (ER) stress response implicated in the development of multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and lymphoma. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - October 13, 2020 Category: Biology Source Type: news

New radioimmunotherapy improves lymphoma treatment
Researchers have found that a new radioimmunotherapy can reverse resistance...Read more on AuntMinnie.comRelated Reading: New radiotracer increases multiple myeloma survival PET/CT pinpoints Hodgkin's lymphoma treatment response PET rules out need for radiotherapy in lymphoma patients Radioimmunotherapy shows promise for curing HIV infection SNMMI touts radioimmunotherapy study (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - October 9, 2020 Category: Radiology Source Type: news

Stand Up To Cancer's Sharp Tank Award goes to multiple myeloma research
(Stand Up To Cancer) Stand Up To Cancer (SU2C) has awarded the 2020 SU2C Sharp Tank Award to research that focuses on interventions in patients with precursor multiple myeloma, with a particular focus on underserved populations. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 1, 2020 Category: Cancer & Oncology Source Type: news

Penn researchers discover potential cause of immunotherapy-related neurotoxicity
(University of Pennsylvania School of Medicine) New research has uncovered the previously unknown presence of CD19 -- a B cell molecule targeted by chimeric antigen receptor (CAR) T cell immunotherapy to treat leukemia, lymphoma, and multiple myeloma -- in brain cells that protect the blood brain barrier (BBB). This discovery may potentially be the cause for neurotoxicity in patients undergoing CD19 directed CAR T cell immunotherapy, according to the research team led by Avery Posey, PhD, an assistant professor of Systems Pharmacology and Translational Therapeutics at the University of Pennsylvania. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 21, 2020 Category: Cancer & Oncology Source Type: news

New partnership to build advanced predictive testing for blood cancer multiple myeloma
(RCSI) By combining genomic testing and next generation sequencing technology, a new partnership led by RCSI researchers aims to advance predictive tests for multiple myeloma (MM), the second most common blood cancer in Ireland. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 17, 2020 Category: Cancer & Oncology Source Type: news

Genomic Profiling Detects Smoldering Multiple Myeloma Risk Genomic Profiling Detects Smoldering Multiple Myeloma Risk
Could genomic profiling accurately predict which patients with smoldering multiple myeloma are at risk for progression? Find out what there is to know.Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 15, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Multiple Myeloma: Types of Treatment
Title: Multiple Myeloma: Types of TreatmentCategory: Diseases and ConditionsCreated: 9/9/2020 12:00:00 AMLast Editorial Review: 9/9/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 9, 2020 Category: Cancer & Oncology Source Type: news

Team approach at Atrium Health saved man ’s life when his situation became dire
Jack Wheeler has lived with multiple myeloma – a blood cancer – for 20 years. But after developing troubling symptoms that quickly got worse, Wheeler ended up hospitalized – in the middle of the COVID-19 pandemic. Quick intervention from an interdisciplinary team across Atrium Health Carolinas Medical Center and Atrium Health Levine Canc er Institute saved his life. Wheeler is now in remission from his cancer and continuing his treatment in a promising clinical trial. Read more about Jack… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 1, 2020 Category: Biotechnology Authors: Atrium Health Source Type: news

ICER assessing CAR-T cell therapies for multiple myeloma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 31, 2020 Category: Drugs & Pharmacology Source Type: news

FDA approves carfilzomib and daratumumab with dexamethasone for multiple myeloma
On August 20, 2020, the Food and Drug Administration approved carfilzomib (KYPROLIS, Onyx Pharmaceuticals, Inc.) and daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received one to three lines o (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 21, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 21, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

RVD Induction Therapy in Newly Diagnosed Multiple Myeloma RVD Induction Therapy in Newly Diagnosed Multiple Myeloma
What benefits might be achieved with a combination lenalidomide, bortezomib, and dexamethasone induction regimen in patients with multiple myeloma?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 17, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news